Evidence map›Paper›PMID 31849474›Full record

ArticleInternational journal of nanomedicine2019

Heterozygous Disruption of

Xuemei Liu, Bin Wang, Xuejun Jiang, Jun Zhang, Qianghu Tang, Yujia Zhang, Xia Qin, Chengzhi Chen, Zhen Zou

Open access · goldAbstract read
In one paragraph

Article in International journal of nanomedicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Beclin1 Deficiency Suppresses Epileptic Seizures.Frontiers in molecular neuroscience · 2022
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Xuemei Liu *Department of Occupational and Environmental Health, School of Public Health and Management, Chongqing Medical University, Chongqing 400016, People's Republic of China.
Bin Wang *Institute of Life Sciences, Chongqing Medical University, Chongqing 400016, People's Republic of China.ORCID 0000-0003-0225-9393
Xuejun JiangCenter of Experimental Teaching for Public Health, Experimental Teaching and Management Center, Chongqing Medical University, Chongqing 400016, People's Republic of China.
Jun ZhangInstitute of Life Sciences, Chongqing Medical University, Chongqing 400016, People's Republic of China.
Qianghu TangDepartment of Occupational and Environmental Health, School of Public Health and Management, Chongqing Medical University, Chongqing 400016, People's Republic of China.
Yujia ZhangDepartment of Occupational and Environmental Health, School of Public Health and Management, Chongqing Medical University, Chongqing 400016, People's Republic of China.
Xia QinDepartment of Pharmacy, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, People's Republic of China.
Chengzhi ChenDepartment of Occupational and Environmental Health, School of Public Health and Management, Chongqing Medical University, Chongqing 400016, People's Republic of China.ORCID 0000-0002-1087-4911
Zhen ZouInstitute of Life Sciences, Chongqing Medical University, Chongqing 400016, People's Republic of China.ORCID 0000-0002-1651-591X
Chongqing Medical University · CNThe Affiliated Yongchuan Hospital of Chongqing Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeLiver is regarded as one of the primary target organs for zinc oxide nanoparticles (ZnONPs) toxicity. Since liver represents the leading site for de novo cholesterol biosynthesis in mammals, the injuries of liver could result in the disruption of cholesterol biosynthesis. In this study, we aimed to investigate whether pulmonary ZnONPs exposure induces disturbance of cholesterol biosynthesis in mouse liver. METHODS AND

resultsOur data demonstrated intratracheally instilled with a single dose of 3, 6, and 12 μg/animal ZnONPs could induce histopathological deterioration in mouse liver in a dose-related manner at 3 days, but remission was observed at 7 days after treatment. Moreover, ZnONPs caused the disturbance of cholesterol biosynthesis by increasing both 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase and sterol regulatory element-binding protein 2 (SREBP2) protein expressions. To further reveal the underlying toxic mechanisms, we detected the biomarkers of autophagy and found that pulmonary ZnONPs exposure led to the elevation of LC3B-II and Beclin 1, suggesting ZnONPs might trigger autophagy in liver tissues. By using both

conclusionPulmonary exposure of ZnONPs would induce the cholesterol biosynthesis disturbance in mouse liver through Beclin-1-dependent autophagy activation, suggesting that inhibition of autophagy may contribute to preventing the cholesterol biosynthesis disturbance and its associated pathologies induced by ZnONPs in liver.

Indexed as

AnimalsAutophagyBeclin-1CholesterolDose-Response Relationship, DrugHeterozygoteLiverLungMaleMetal NanoparticlesMice, Inbred C57BLMice, Mutant StrainsZinc OxideBeclin-1Becn1 protein, mouseCholesterolZinc Oxideautophagybeclin 1cholesterol biosynthesisliverzinc oxide nanoparticles

Identifiers

PMID31849474
PMCPMC6913297
OpenAlexW2995455361

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.